T1	Intervention 25 35	evolocumab
T2	Intervention 125 143	placebo-controlled
T3	Intervention 443 453	Evolocumab
T4	Intervention 457 476	monoclonal antibody
T5	Intervention 480 525	proprotein convertase subtilisin/kexin type 9
T6	Intervention 611 621	evolocumab
T7	Intervention 653 671	placebo-controlled
T8	Intervention 726 744	placebo-controlled
T9	Intervention 952 986	on stable lipid-regulating therapy
T10	Intervention 1139 1188	receive subcutaneous evolocumab 420 mg or placebo
T11	Intervention 1323 1374	by a computerised interactive voice-response system
T12	Intervention 1979 1990	the placebo
T13	Intervention 2007 2021	the evolocumab
T14	Intervention 2039 2063	with placebo, evolocumab
T15	Intervention 2246 2261	patients in the
T16	Intervention 2292 2312	33 in the evolocumab
T17	Intervention 2383 2401	no anti-evolocumab
T18	Intervention 2592 2613	apheresis, evolocumab
T19	Intervention 2709 2722	compared with
